Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 30.7% in January

Athira Pharma, Inc. (NASDAQ:ATHA) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 949,500 shares, a decrease of 30.7% from the January 15th total of 1,370,000 shares. Based on an average daily volume of 443,300 shares, the days-to-cover ratio is currently 2.1 days. Approximately 2.7% of the company’s stock are short sold.

Athira Pharma Stock Performance

ATHA stock traded up $0.03 during trading on Friday, hitting $0.47. 126,368 shares of the stock traded hands, compared to its average volume of 208,878. The firm’s 50 day moving average is $0.54 and its two-hundred day moving average is $0.99. Athira Pharma has a 1 year low of $0.41 and a 1 year high of $4.30.

Institutional Trading of Athira Pharma

A number of institutional investors have recently made changes to their positions in ATHA. BML Capital Management LLC purchased a new stake in shares of Athira Pharma during the 4th quarter valued at about $1,629,000. GSA Capital Partners LLP lifted its stake in shares of Athira Pharma by 909.8% in the 3rd quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock worth $177,000 after purchasing an additional 357,787 shares during the period. Finally, Bristlecone Advisors LLC lifted its stake in shares of Athira Pharma by 295.6% in the 3rd quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock worth $151,000 after purchasing an additional 252,200 shares during the period. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.